Luxendo, a Heidelberg, Germany-based developer of proprietary Single Plane Illumination Microscopy (SPIM) technology for biomedical research, raised additional funding as part of Series A round now totalling €8m.
The extension round was led by Life Science Partners (LSP), Amsterdam, EMBL Ventures, Heidelberg and EMBL Enterprise Management Technology Transfer.
The company intends to use funds to expand its international sales and marketing team.
Founded in October 2015 as a spin out of the European Molecular Biology Laboratory, Luxendo develops and internationally markets its Single Plane Illumination Microscopes which are based on its proprietary Single Plane Illumination Microscopy (SPIM) technology.
The company – led by Andreas Pfuhl, CEO – currently markets:
The MuVi-SPIM microscope, which allows fast 3D imaging of living objects such as spheroids and whole specimens for extended periods of time, and without the need of sample rotation.
– The InVi-SPIM microscope, which allows extremely gentle sample handling. It is designed for fast 3D imaging of living objects such as cell cultures and developing embryonic samples.